deucravacitinib,apremilast
bms,amgen
['psoriasis', 'deucrava', 'deucra', '$bmy', 'bristol']
$bmy bristol myers squibb announces new sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft